Download PDF
Arzneimittelforschung 2011; 61(12): 707-713
DOI: 10.1055/s-0031-1300591
Anti-osteoporosis Drugs
Editio Cantor Verlag Aulendorf (Germany)

Drug-drug interaction study between a novel oral ibandronate formulation and metformin

Beate Bittner
1   F. Hoffmann-La Roche Ltd., Clinical Pharmacology, Basel, Switzerland
,
Christine Mclntyre
1   F. Hoffmann-La Roche Ltd., Clinical Pharmacology, Basel, Switzerland
,
Paul Jordan
2   F. Hoffmann-La Roche Ltd., Biostatistics, Basel, Switzerland
,
Johannes Schmidt
3   F. Hoffmann-La Roche Ltd., Pharma Medicines Global Product Strategy, Basel, Switzerland
› Author Affiliations
Further Information

Publication History

Publication Date:
09 February 2012 (online)

    Permissions and Reprints

Abstract

The novel excipient, sodium N-[8-(2-hy-droxybenzoyl)amino]caprylate (SNAC, CAS 203787-91-1) increases the oral bioavailability of co-formulated ibandronate (IBN, CAS 138926-19). The aim of this study was to investigate the effect of the IBN/SNAC formulation on the steady-state pharmacokinetics of metformin (CAS 657-24-9) and to assess safety and tolerability of IBN/SNAC when dosed in combination with metformin. Twenty-two healthy subjects received metformin on Days 1 to 6. On Day 7, subjects received metformin together with the IBN/ SNAC formulation. The safety and tolerability of IBN/SNAC co-administered with metformin was consistent with the known safety profile of the single medications. The increase in mean maximum plasma concentration (Cmax) and mean overall exposure to metformin (AUC0–τ) was approximately 7%. The entire 90% confidence intervals for the AUC- and Cmax-ratios did fall within the acceptance region for bioequivalence (0.8-1.25). In summary, administration of the IBN/ SNAC formulation together with metformin did not lead to a significant increase in exposure to metformin. The study medication was well tolerated in healthy volunteers.

Key words

Drug-drug interaction - Ibandronate - Metformin - SNAC
 

  • References

  • 1 Chesnut III CH, Skag A, Christiansen C, Recker R, Stakke-stad JA, Hoiseth A et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004; 19: 1241-9
    CrossrefPubMedGoogle Scholar
  • 2 Miller PD, McClung MR, Macovei L, Stakkestad JA, Luckey M, Bonvoisin B et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res. 2005; Aug; 20 (8) 1315-22
    CrossrefPubMedGoogle Scholar
  • 3 Reginster JY, Adami S, Lakatos P, Greenwald M, Stepan JJ, Silverman SL et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2-year results from the MOBILE study. Ann Rheum Dis. 2006; May; 65 (5) 654-61
    CrossrefPubMedGoogle Scholar
  • 4 Barrett J, Worth E, Bauss F, Epstein S. Ibandronate: A clinical pharmacological and pharmacokinetic update. J Clin Pharmacol. 2004; Sep; 44 (9) 951-65
    PubMedGoogle Scholar
  • 5 Leone-Bay A, Paton DR, Variano B, Leipold H, Rivera T, Miura-Fraboni J et al. Acylated non-alpha-amino acids as novel agents for the oral delivery of heparin sodium, USP. J Control Release. 1998; 50: 41-9
    CrossrefPubMedGoogle Scholar
  • 6 Tucker GT, Casey C, Phillips PJ, Connor H, Ward JD, Woods HF. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol. 1981; Aug; 12 (2) 235-46
    CrossrefPubMedGoogle Scholar
  • 7 Song NN, Zhang SY, Liu CX. Overview of factors affecting oral drug absorption. Asian J Drug Metab Pharmacokinet. 2004; Aug; 4 (3) 167-76
    PubMedGoogle Scholar
  • 8 Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone. 1996; Feb; 18 (2) 75-85
    CrossrefPubMedGoogle Scholar
  • 9 Brayden D, Creed E, O’Connell A, Leipold H, Agarwal R, Leone-Bay A. Heparin absorption across the intestine: effects of sodium N-[8-(2-hydroxybenzoyl)amino]caprylate in rat in situ intestinal instillations and in caco-2 monolayers. Pharm Res. 1997; 14: 1772-9
    CrossrefPubMedGoogle Scholar
  • 10 Malkov D, Wang HZ, Dinh S, Gomez-Orellana I. Pathway of oral absorption of heparin with sodium N-[8-(2-hydroxy-benzoyl)amino]caprylate. Pharm Res. 2002; 19: 1180-4
    CrossrefPubMedGoogle Scholar
  • 11 Malkov D, Angelo R, Wang HZ, Flanders E, Tang H, Gomez-Orellana I. Oral delivery of insulin with the eligen technology: mechanistic studies. Curr Drug Deliv. 2005; 2: 191-7
    CrossrefPubMedGoogle Scholar
  • 12 Wu SJ, Robinson JR. Transport of human growth hormone across caco-2 cells with novel delivery agents: Evidence for p-glycoprotein involvement. J Control Release. 1999; 62: 171-7
    CrossrefPubMedGoogle Scholar
  • 13 Wu SJ, Robinson JR. Transcellular and lipophilic complex-enhanced intestinal absorption of human growth hormone. Pharm Res. 1999; Aug; 16 (8) 1266-72
    CrossrefPubMedGoogle Scholar
  • 14 Leone-Bay A, Sato M, Paton D, Hunt AH, Sarubbi D, Caroz-za M et al. Oral delivery of biologically active parathyroid hormone. Pharm Res. 2001; March; 18 (7) 964-70
    CrossrefPubMedGoogle Scholar
  • 15 Ding X, Rath P, Angelo R, Stringfellow T, Flanders E, Dinh S et al. Oral absorption enhancement of cromolyn sodium through non-covalent complexation. Pharm Res. 2004; Dec; 21 (12) 2196-206
    CrossrefPubMedGoogle Scholar
  • 16 Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995; Mar; 12 (3) 413-20
    CrossrefPubMedGoogle Scholar
  • 17 Noel M. Kinetic study of normal and sustained release dosage forms of metformin in normal subjects. Res Clin Forums. 1979; l (4) 33-44
    PubMedGoogle Scholar
  • 18 Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 1996; May; 30 (5) 359-71
    CrossrefPubMedGoogle Scholar
  • 19 Proctor WR, Bourdet DL, Thakker DR. Mechanisms underlying saturable intestinal absorption of metformin. Drug Metab Dispos. 2008; 36: 1650-8
    CrossrefPubMedGoogle Scholar